Live Breaking News & Updates on Azeria Therapeutics

Stay updated with breaking news from Azeria therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Scottish spin-out raises funds in battle to overcome cancer


Steve Myatt, the newly-appointed chief executive of Macomics
By Kristy Dorsey
Macomics, a drug discovery spin-out from the University of Edinburgh, has raised a further £4.2 million in funding and announced three new senior appointments as it progresses its work in the field of tackling cancer tumours.
The deal was led by transatlantic scientific investors Epidarex Capital following initial seed funding of £3.2m from Epidarex and the Scottish Investment Bank in the middle of last year. Edinburgh-based investment fund Caribou Property has joined as a new investor in this latest round.
Co-founded in 2019 by the university’s Jeffrey Pollard and Luca Cassetta, Macomics is focused on the role of macrophages in increasing the body’s immune defence against tumours. It has R&D and office facilities in Edinburgh and Cambridge. ....

United Kingdom , City Of , Luca Cassetta , Robert Haigh , Steve Myatt , Jeffrey Pollard , Scottish Investment Bank , Epidarex Capital , Caribou Property , Azeria Therapeutics , ஒன்றுபட்டது கிஂக்டம் , நகரம் ஆஃப் , லூகா கேசட்டா , ராபர்ட் ஹை , ஜெஃப்ரி பொழிலர்ட் , ஸ்காட்டிஷ் முதலீடு வங்கி , கரிபூ ப்ராபர்டீ ,

Macomics Ltd: Macomics, the Macrophage-based Drug Discovery company, secures £4.24m expansion financing, and appoints CEO, CSO and VP Immunology


(0)
Follow-on investment, led by Epidarex Capital, closes at £4.24m, following initial £3.2m Seed round in 2020; Caribou Property joins as new investor
Management appointments expand leadership team: Dr Steve Myatt, ex Azeria Therapeutics, to Chief Executive Officer; Dr Carola Ries, ex Roche, to Chief Scientific Officer; Co-founder Dr Luca Cassetta to move from his academic role at Edinburgh University to join as full-time VP Immunology
Funds will accelerate macrophage-based therapeutics R&D portfolio and target discovery capability; expansion of facilities in Edinburgh and Cambridge
Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, announces today that it has closed a follow-on financing of £4.24 million from its 2020 Seed round, bringing the total amount raised to £7.44m. ....

United States , United Kingdom , City Of , Sue Charles , Jeffrey Pollard , Luca Cassetta , Kostenloser Wertpapierhandel , Elizabeth Roper , Steve Myatt , Jan Robertson , Georges Aboud , Caribou Property , Nature Communications , Centre For Reproductive Health , Boston Pharmaceuticals , University Of Edinburgh , Edinburgh University , S Raffaele Institute , Cancer Research Technology , Business Development , Macomics Ltd , Epidarex Capital , Azeria Therapeutics , Chief Executive Officer , Chief Scientific Officer , Co Founder Dr Luca Cassetta ,